These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 27245685)

  • 1. Development and clinical application of an integrative genomic approach to personalized cancer therapy.
    Uzilov AV; Ding W; Fink MY; Antipin Y; Brohl AS; Davis C; Lau CY; Pandya C; Shah H; Kasai Y; Powell J; Micchelli M; Castellanos R; Zhang Z; Linderman M; Kinoshita Y; Zweig M; Raustad K; Cheung K; Castillo D; Wooten M; Bourzgui I; Newman LC; Deikus G; Mathew B; Zhu J; Glicksberg BS; Moe AS; Liao J; Edelmann L; Dudley JT; Maki RG; Kasarskis A; Holcombe RF; Mahajan M; Hao K; Reva B; Longtine J; Starcevic D; Sebra R; Donovan MJ; Li S; Schadt EE; Chen R
    Genome Med; 2016 Jun; 8(1):62. PubMed ID: 27245685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
    Sun JX; He Y; Sanford E; Montesion M; Frampton GM; Vignot S; Soria JC; Ross JS; Miller VA; Stephens PJ; Lipson D; Yelensky R
    PLoS Comput Biol; 2018 Feb; 14(2):e1005965. PubMed ID: 29415044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
    Kaur P; Porras TB; Ring A; Carpten JD; Lang JE
    Sci Rep; 2019 Feb; 9(1):1482. PubMed ID: 30728399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.
    Arango NP; Brusco L; Mills Shaw KR; Chen K; Eterovic AK; Holla V; Johnson A; Litzenburger B; Khotskaya YB; Sanchez N; Bailey A; Zheng X; Horombe C; Kopetz S; Farhangfar CJ; Routbort M; Broaddus R; Bernstam EV; Mendelsohn J; Mills GB; Meric-Bernstam F
    Oncotarget; 2017 Jun; 8(26):41806-41814. PubMed ID: 28415679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
    Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
    Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.
    Garralda E; Paz K; López-Casas PP; Jones S; Katz A; Kann LM; López-Rios F; Sarno F; Al-Shahrour F; Vasquez D; Bruckheimer E; Angiuoli SV; Calles A; Diaz LA; Velculescu VE; Valencia A; Sidransky D; Hidalgo M
    Clin Cancer Res; 2014 May; 20(9):2476-84. PubMed ID: 24634382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized genomic analyses for cancer mutation discovery and interpretation.
    Jones S; Anagnostou V; Lytle K; Parpart-Li S; Nesselbush M; Riley DR; Shukla M; Chesnick B; Kadan M; Papp E; Galens KG; Murphy D; Zhang T; Kann L; Sausen M; Angiuoli SV; Diaz LA; Velculescu VE
    Sci Transl Med; 2015 Apr; 7(283):283ra53. PubMed ID: 25877891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine.
    Van Allen EM; Robinson D; Morrissey C; Pritchard C; Imamovic A; Carter S; Rosenberg M; McKenna A; Wu YM; Cao X; Chinnaiyan A; Garraway L; Nelson PS
    Oncotarget; 2016 Aug; 7(33):52888-52899. PubMed ID: 27167109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.
    Ramkissoon SH; Bandopadhayay P; Hwang J; Ramkissoon LA; Greenwald NF; Schumacher SE; O'Rourke R; Pinches N; Ho P; Malkin H; Sinai C; Filbin M; Plant A; Bi WL; Chang MS; Yang E; Wright KD; Manley PE; Ducar M; Alexandrescu S; Lidov H; Delalle I; Goumnerova LC; Church AJ; Janeway KA; Harris MH; MacConaill LE; Folkerth RD; Lindeman NI; Stiles CD; Kieran MW; Ligon AH; Santagata S; Dubuc AM; Chi SN; Beroukhim R; Ligon KL
    Neuro Oncol; 2017 Jul; 19(7):986-996. PubMed ID: 28104717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
    Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
    Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level.
    Rangel-Pozzo A; Liu S; Wajnberg G; Wang X; Ouellette RJ; Hicks GG; Drachenberg D; Mai S
    Cells; 2020 Aug; 9(8):. PubMed ID: 32784507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physician interpretation of genomic test results and treatment selection.
    Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
    Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
    Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
    Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
    [No Abstract]   [Full Text] [Related]  

  • 16. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study.
    Ghazani AA; Oliver NM; St Pierre JP; Garofalo A; Rainville IR; Hiller E; Treacy DJ; Rojas-Rudilla V; Wood S; Bair E; Parello M; Huang F; Giannakis M; Wilson FH; Stover EH; Corsello SM; Nguyen T; Rana HQ; Church AJ; Lowenstein C; Cibulskis C; Amin-Mansour A; Heng J; Brais L; Santos A; Bauer P; Waldron A; Lo P; Gorman M; Lydon CA; Welch M; McNamara P; Gabriel S; Sholl LM; Lindeman NI; Garber JE; Joffe S; Van Allen EM; Gray SW; Ja Nne PA; Garraway LA; Wagle N
    Genet Med; 2017 Jul; 19(7):787-795. PubMed ID: 28125075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.
    Chang W; Brohl AS; Patidar R; Sindiri S; Shern JF; Wei JS; Song YK; Yohe ME; Gryder B; Zhang S; Calzone KA; Shivaprasad N; Wen X; Badgett TC; Miettinen M; Hartman KR; League-Pascual JC; Trahair TN; Widemann BC; Merchant MS; Kaplan RN; Lin JC; Khan J
    Clin Cancer Res; 2016 Aug; 22(15):3810-20. PubMed ID: 26994145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
    Fernández-Navarro P; López-Nieva P; Piñeiro-Yañez E; Carreño-Tarragona G; Martinez-López J; Sánchez Pérez R; Aroca Á; Al-Shahrour F; Cobos-Fernández MÁ; Fernández-Piqueras J
    BMC Cancer; 2019 Oct; 19(1):1005. PubMed ID: 31655559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.
    Oberg JA; Glade Bender JL; Sulis ML; Pendrick D; Sireci AN; Hsiao SJ; Turk AT; Dela Cruz FS; Hibshoosh H; Remotti H; Zylber RJ; Pang J; Diolaiti D; Koval C; Andrews SJ; Garvin JH; Yamashiro DJ; Chung WK; Emerson SG; Nagy PL; Mansukhani MM; Kung AL
    Genome Med; 2016 Dec; 8(1):133. PubMed ID: 28007021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
    Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
    PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.